vx-702 and Syndrome

vx-702 has been researched along with Syndrome* in 1 studies

Other Studies

1 other study(ies) available for vx-702 and Syndrome

Article	Year
Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:11 Vertex Pharmaceuticals Inc, in collaboration with Kissei Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006. Topics: Acute Disease; Administration, Oral; Arthritis, Rheumatoid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Disease; Drug Evaluation; Enzyme Inhibitors; Humans; p38 Mitogen-Activated Protein Kinases; Patents as Topic; Phenylurea Compounds; Syndrome	2006

Article

Year

Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.

Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:11

Vertex Pharmaceuticals Inc, in collaboration with Kissei Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.

Topics: Acute Disease; Administration, Oral; Arthritis, Rheumatoid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Disease; Drug Evaluation; Enzyme Inhibitors; Humans; p38 Mitogen-Activated Protein Kinases; Patents as Topic; Phenylurea Compounds; Syndrome

2006